pocketful logo light
pocketful logo light
Natco Pharma Ltd logo

Natco Pharma Ltd

NSE: NATCOPHARM BSE: 524816

815.35

(0.40%)

Thu, 17 Sept 2026, 09:27 am

Natco Pharma Share Price Live Chart

1 Day

(0.40%)

No Result Found

Summary

  • Market Cap (in Cr)

    18211

  • Net Profit (in Cr)

    1883.4

  • P/B

    1.88

  • Sector P/E

    33.76

  • P/E

    7.57

  • EV/EBITDA

    4.85

  • Debt/Equity (Industry)

    0.24

  • Interest Cover (Industry)

    9.79

  • ROCE (Industry)

    14.04

  • RONW (Industry)

    13.17

  • ROE

    27.98

  • ROCE

    32.48

  • Debt/Equity

    0.05

  • EPS (TTM)

    86.94

  • Dividend Yield

    0.59

  • Book Value

    482.93

  • Interest Cover

    96.87

Analysis

all

thumbs up icon

Pros

  • Dividends per share have increased over the past 10 years.
  • Dividends paid are well covered by earnings (3.8x coverage).
  • Dividends after 3 years are expected to be thoroughly covered by earnings (9.2x coverage).
  • NATCO Pharma's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
  • Cash flow for NATCO Pharma is expected to increase by more than 50% in 2 years time.
thumbs up icon

Cons

  • Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
  • NATCO Pharma's dividend is below the markets top 25% of dividend payers in India (3.08%).
  • NATCO Pharma's net income is expected to increase but not above the 50% threshold in 2 years time.
  • NATCO Pharma's revenue is expected to increase but not above the 50% threshold in 2 years time.
  • NATCO Pharma's revenue is expected to grow by 15.7% yearly, however this is not considered high growth (20% yearly).

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters49.4249.4849.4849.5649.56
FII17.3715.1614.0915.5117.49
DII5.465.395.875.825.65
Public27.7529.9630.5629.1127.29
Government0.000.000.000.000.00

Read More

Technical Analysis

RSI

32.16

MACD

-23.36

50 DMA

896.33

200 DMA

944.41

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic1139.321009.97925.73880.62796.38751.27621.92
Fibonacci1009.97960.55930.03880.62831.20800.68751.27
Camarilla877.07865.21853.36880.62829.64817.79805.93

Pivots Level: Classic

R3

+258.70

1139.32

R2

+129.35

1009.97

R1

+45.12

925.73

880.62
880.62
Pivot Point
LTP: 817.55

S1

-84.23

796.38

S2

-129.35

751.27

S3

-258.70

621.92

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    825.89

  • 20-EMA

    843.19

  • 30-EMA

    858.51

  • 50-EMA

    883.07

  • 100-EMA

    916.69

  • 200-EMA

    934.37

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
29 May 2026board-meetingsAccounts
12 Feb 2026board-meetingsQuarterly Results, Interim Dividend
12 Feb 2026dividend₹1.50 Dividend /Share18 Feb 2026
18 Jan 2026dividendInterim Dividend - Rs 1.50 Per Share18 Feb 2026
14 Nov 2025board-meetingsQuarterly Results, Interim Dividend
14 Nov 2025dividend₹1.50 Dividend /Share20 Nov 2025
20 Oct 2025dividendInterim Dividend - Rs. - 1.520 Nov 2025
28 Aug 2025agm
12 Aug 2025dividend₹2.00 Dividend /Share19 Aug 2025
19 Jul 2025dividendInterim Dividend - Rs. - 219 Aug 2025

Read More

Peer Comparison

Natco Pharma Ltd logo

Natco Pharma Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Cipla Ltd logo

Cipla Ltd

Read More

Natco Pharma Ltd About

Natco Pharma is engaged in the business of pharmaceuticals and agricultural chemicals which comprises research and development, manufacturing and selling of bulk drugs, finished dosage formulations.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1981

Headquarters

CEO

V C Nannapaneni

Employees

Contact

Website icon

Website

http://www.natcopharma.co.in

Email icon

Email

investors@natcopharma.co.in

Phone icon

Phone

91-040-23547532

Location icon

Location

Natco House, Road No 2 Banjara Hills, Hyderabad, Telangana, 500033

Read More

Natco Pharma Ltd Company History

YearHistory
2020
  • Announced launch of Lapatinib Tablets for breast cancer in US.
  • Supported Columbia University's clinical trial of chloroquine phosphate for Covid-19.
  • Received establishment inspection report (EIR) for Kothur formulation facility.
  • Vizag formulation facility received USFDA approval.
2021
  • Launched Tipanat tablets in India for advanced colorectal and gastric cancer.
  • Announced launch of 10mg strength Everolimus Tablets (generic for Afinitor) in US market.
  • Natco Pharma (Canada) Inc. launched PrNAT-LENALIDOMIDE Capsules, first generic alternative to Revlimid.
  • Received approval for Carfilzomib Vials ANDA (generic for KYPROLIS) in US market.
  • Signed Voluntary Licensing Agreement with Lilly for Baricitinib for Covid-19 in India.
  • Received final approval for Everolimus tablets (generic for Afinitor) for US market.
2022
  • Launched Chlorantraniliprole (CTPR) product NATGEN.
  • Signed license agreement with Medicines Patent Pool, Switzerland.
  • Awarded Corporate Governance Award.
  • Completed acquisition of Dash Pharmaceuticals LLC.
2023
  • Launched generic Pomalidomide Capsules in Canada.
  • Received final approval for Tipiracil Hydrochloride and Trifluridine (generic for Lonsurf) for the US market.
2024
  • Partner Mylan settles patent litigation with Novo Nordisk over generic Ozempic in US.

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
GRAVITON RESEARCH CAPITAL LLPbulkBuy1199044904.1926 Nov 2025
GRAVITON RESEARCH CAPITAL LLPbulkSell1199411904.9326 Nov 2025
GRAVITON RESEARCH CAPITAL LLPbulkBuy1784917929.7124 Apr 2025
GRAVITON RESEARCH CAPITAL LLPbulkSell1784917930.1924 Apr 2025
GRAVITON RESEARCH CAPITAL LLPbulkSell971727891.0314 Feb 2025
GRAVITON RESEARCH CAPITAL LLPbulkBuy971727890.8614 Feb 2025
THE JUPITER GLOBAL FUND-JUPITER INDIA SELECTblockBuy1987421039.1521 Feb 2024
JUPITER SOUTH ASIA INVESTMENT COMPANY LIMITEDblockSell1987421039.1521 Feb 2024
MARSHALLWACEINVESTMENTSTRATEGIESMARKETNEUTRALTOPSFUNDblockBuy149926859.225 Jan 2024
BNP PARIBAS ARBITRAGEblockSell149926859.225 Jan 2024

Read More

Natco Pharma Ltd News

Natco Pharma Gets Tentative FDA Nod for Olaparib Tablets

Natco Pharma receives tentative FDA approval for Olaparib Tablets, with Alembic Pharmaceuticals set to distribute in the U.S., where the drug sees ~$1.4 billion in sales by March 2026.

18 Jul 2026

companies

Natco Pharma gets GST order

Natco Pharma received a GST order demanding Rs 60 lakh. The demand includes tax, interest, and penalty for RCM discrepancies.

14 Jul 2026

companies

Natco Pharma to Raise Adcock Ingram Stake to 49%

Natco Pharma plans to increase its stake in Adcock Ingram from 35.75% to 49% by acquiring 19.6 million shares for ₹1,069 crore, alongside a ₹1,400 crore investment in its South Africa subsidiary.

08 Jul 2026

companies

Natco Pharma appoints two senior VPs

Natco Pharma designated Gnanadeva Chalapathy Gudipati as Senior Vice President and Madhava Rao Karicherla as Vice President effective July 6, 2026.

06 Jul 2026

companies

Natco Pharma VP Operations superannuates

Nadella Malleswara Rao superannuated as VP - Operations on June 30, 2026. The change was disclosed under SEBI regulations.

30 Jun 2026

companies

Read More

Frequently Asked Questions

  • 1.What is the stock price of Natco Pharma Ltd?

    As of 17/09/2026 at 2:57 PM, Natco Pharma Ltd shares are trading at 815.35.

  • 2.What is the market cap. of Natco Pharma Ltd?

    As of 17/09/2026, the market capitalization of Natco Pharma Ltd is 14,669.10 crore.

  • 3.When was Natco Pharma Ltd founded?

    Natco Pharma Ltd was founded in 1981.

  • 4.What are the P/E and P/B ratios of Natco Pharma Ltd?

    As of 17/09/2026, Natco Pharma Ltd has a P/E ratio of 12.76 and a P/B ratio of 1.88.

  • 5.How can I buy shares of Natco Pharma Ltd?

    You can buy shares of Natco Pharma Ltd through Pocketful. Simply open a Demat account, complete your KYC, add funds, and place a buy order.

  • 6.What is the shareholding pattern of Natco Pharma Ltd?

    As of March,2026, promoters hold 49.42% in Natco Pharma Ltd, while FIIs, DIIs and public shareholders hold 17.37%, 5.46% and 27.75%, respectively. The government holds 0.00%.

  • 7.Does Natco Pharma Ltd pay dividends?

    Yes, Natco Pharma Ltd pays dividends to eligible shareholders. The latest dividend announced by the company was ₹1.50 Dividend /Share per share.

  • 8.What is the dividend yield of Natco Pharma Ltd?

    As of 17 September, 2026, the dividend yield of Natco Pharma Ltd stands at 0.55%.

  • 9.What are the latest financial results of Natco Pharma Ltd?

    For January,2024, Natco Pharma Ltd reported revenue of 4,415.00 crore and a net profit of 1,885.00 crore.

  • 10.What is the Stock symbol of Natco Pharma Ltd?

    NATCOPHARM is the stock symbol of Natco Pharma Ltd.

  • 11.Who is the CEO of Natco Pharma Ltd?

    The CEO of Natco Pharma Ltd is V C Nannapaneni.

Open Your Free Demat Account

Enter your phone number